Gapping up
In reaction to strong earnings/guidance: SLP +9.2%, OZRK +1%, JNJ +0.8%, JPM +0.3%
M&A news: MU +12.4% (WSJ report that Tsinghua Unigroup is set to make $21/share offer for MU, Reuters cited MU spokesman denying that offer was received)
Other news: BIOC +15.5% (commercial launch of its proprietary, quantitative assay, targeting BRAF mutations utilizing a patient's blood sample), NVGN +6.1% (announces details of an in vivo proof of concept study that demonstrates Anisina has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects), SNDK +2.9% (MU peer),TNK +2.8% (filed for $150 mln offering of Class A common stock), AMD +2.6% (MU peer), BOX +2.4% (favorable commentary on Monday's Mad Money), REXX +2.2% (still checking), VLO +1.8% (announced Board approval of an incremental $2.5 bln share repurchase authorization), FIT +1.6% (cont vol post IPO), BLDP +1.4% (initiated with a Buy at H.C. Wainwright), AMAT+1.2% (hosted inv conf, targets non-GAAP EPS of $2.00 in 2018), WWE +1.1% (Talpa Beheer B.V. discloses 6.0% passive stake in 13G filing), PGN +1% (announced fleet status as of July 13), AZN +1% (receives FDA approval for IRESSA for patients with NSCLC), JRJC +1% (regains compliance with Nasdaq)
Analyst comments: CYAD +9.1% (initiated with a Buy at UBS, among others), OCUL +9% (initiated with a Buy at BTIG Research), CLSN +7.8% (initiated with a Buy at BTIG Research), GPRO +3.1% (upgraded to Overweight from Equal Weight at Barclays), DK +2.2% (upgraded to Buy from Neutral at Goldman), Z +1.9% (initiated with a Overweight at Morgan Stanley), MB+1.8% (initiated with a Neutral at BTIG Research, among others), URBN +1.8% (upgraded to Buy from Hold at Jefferies), AMZN +1.5% (upgraded to Buy from Neutral at UBS), BIIB +1.3% (upgraded to Buy from Neutral at BofA/Merrill), CCL +1% (upgraded to Hold from Underperform at Jefferies), KO +0.6% (upgraded to Buy from Neutral at UBS)
In reaction to strong earnings/guidance: SLP +9.2%, OZRK +1%, JNJ +0.8%, JPM +0.3%
M&A news: MU +12.4% (WSJ report that Tsinghua Unigroup is set to make $21/share offer for MU, Reuters cited MU spokesman denying that offer was received)
Other news: BIOC +15.5% (commercial launch of its proprietary, quantitative assay, targeting BRAF mutations utilizing a patient's blood sample), NVGN +6.1% (announces details of an in vivo proof of concept study that demonstrates Anisina has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects), SNDK +2.9% (MU peer),TNK +2.8% (filed for $150 mln offering of Class A common stock), AMD +2.6% (MU peer), BOX +2.4% (favorable commentary on Monday's Mad Money), REXX +2.2% (still checking), VLO +1.8% (announced Board approval of an incremental $2.5 bln share repurchase authorization), FIT +1.6% (cont vol post IPO), BLDP +1.4% (initiated with a Buy at H.C. Wainwright), AMAT+1.2% (hosted inv conf, targets non-GAAP EPS of $2.00 in 2018), WWE +1.1% (Talpa Beheer B.V. discloses 6.0% passive stake in 13G filing), PGN +1% (announced fleet status as of July 13), AZN +1% (receives FDA approval for IRESSA for patients with NSCLC), JRJC +1% (regains compliance with Nasdaq)
Analyst comments: CYAD +9.1% (initiated with a Buy at UBS, among others), OCUL +9% (initiated with a Buy at BTIG Research), CLSN +7.8% (initiated with a Buy at BTIG Research), GPRO +3.1% (upgraded to Overweight from Equal Weight at Barclays), DK +2.2% (upgraded to Buy from Neutral at Goldman), Z +1.9% (initiated with a Overweight at Morgan Stanley), MB+1.8% (initiated with a Neutral at BTIG Research, among others), URBN +1.8% (upgraded to Buy from Hold at Jefferies), AMZN +1.5% (upgraded to Buy from Neutral at UBS), BIIB +1.3% (upgraded to Buy from Neutral at BofA/Merrill), CCL +1% (upgraded to Hold from Underperform at Jefferies), KO +0.6% (upgraded to Buy from Neutral at UBS)